Amylin, Lilly Wrap Up Diabetes Drug Alliance, Lawsuit
By Eric Hornbeck ( November 8, 2011, 7:13 PM EST) -- Amylin Pharmaceuticals Inc. said Tuesday that it would pay Eli Lilly & Co. $250 million now and up to $1.2 billion later to end a lucrative diabetes drug joint marketing agreement that spurred contentious antitrust litigation between the two drugmakers....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.